Mabylon
an innovator in the high-throughput discovery, characterisation, and development of human-derived antibodies
Mabylon has raised €32M across 1 funding round from 1 investor, most recently a round in Aug 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Zurich, Switzerlandwww.mabylon.com ↗
Total raised
€32M
€31,800,000
Funding rounds
1
Investors
1
distinct backers
Active since
2025-08
latest 2025-08
Funding by year
EUR raised per yearMabylon — funding by year — interactive chart.
Data table
| Mabylon — funding by year | |
|---|---|
| 2025 | €32M |
Signals
Medium confidenceRaise-next likelihood47
base rate 30% for Other
- ▲ In typical raise window
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-12 | Other | €32M | existing private investors | View deal → |
Investors
1existing private investors
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData